COR
CencoraDNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-18
Current thesis
The strongest post-print argument is that the market can look past a modest consensus miss because the company raised FY2026 adjusted EPS guidance to $17.65-$17.90, cited strong U.S. Healthcare Solutions operating-income growth, and showed OneOncology already helping mix and gross profit [#8-K-2026-05-06].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Acquisition financing materially increased debt: total debt rose to about $12.4 billion at March 31, 2026 from about $7.7 billion at September 30, 2025, raising interest-cost sensitivity after OneOncology [#10-Q-2026-05-06].
Momentum
34
Value
58
Sentiment
47
Setup hits (3d)
— · Net —
AI TargetsBase $275.00 · Bull $300.00 · Bear $235.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net —
Target $353.50
Why
Momentum34 · Δ7d -1.0
Value58 · Δ7d -0.1
Sentiment47 · Δ7d -4.1
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
34
26% active weight
Current posture
7d trendImproving
Δ7d
-1.0
Δ21d
+2.5
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-3.5
Sentiment
47
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.1
Δ21d
-8.3
Why this grade
Composite grade D. Momentum 34.0 / Value 57.8 / Sentiment 47.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$59.91B
Beta
0.68
Shares Out
194.56M
P/E (TTM)
42.9
P/S (TTM)
0.21
P/FCF (TTM)
23.88
Rev YoY
+3.8%
EPS YoY
+128.3%
Gross Margin
+3.5%
Op Margin
+0.8%
Net Debt
$4.94B
Current Ratio
0.95
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology